Skip to main content
TipRanks
Go Ultimate75% OFF

Lexaria Bioscience (LEXX) Ratios

252 Followers

Lexaria Bioscience Ratios

LEXX's free cash flow for Q3 2026 was $-1.66M. For the 2026 fiscal year, LEXX's free cash flow was decreased by $-26.25K and operating cash flow was $-1.64M. See a summary of the company’s cash flow.

Financial ratios
RatiosAug 25Aug 24Aug 23Aug 22Aug 21
Liquidity Ratios
Current Ratio2.327.188.2235.9681.18
Quick Ratio2.327.188.2235.7680.99
Cash Ratio1.215.915.0529.9671.23
Solvency Ratio-7.51-4.73-16.14-35.36-19.09
Operating Cash Flow Ratio-7.00-4.51-21.97-25.15-26.03
Short-Term Operating Cash Flow Coverage0.000.000.000.00-503.37
Net Current Asset Value$ 1.90M$ 6.69M$ 1.80M$ 6.78M$ 12.24M
Leverage Ratios
Debt-to-Assets Ratio0.030.020.050.010.01
Debt-to-Equity Ratio0.040.020.050.010.01
Debt-to-Capital Ratio0.040.020.050.010.01
Long-Term Debt-to-Capital Ratio0.000.000.000.000.00
Financial Leverage Ratio1.401.101.010.991.00
Debt Service Coverage Ratio0.000.000.000.00-506.76
Interest Coverage Ratio0.000.000.000.000.00
Debt to Market Cap0.000.000.000.000.00
Interest Debt Per Share0.090.010.020.010.02
Net Debt to EBITDA0.141.110.180.802.69
Profitability Margins
Gross Profit Margin99.61%82.56%23.86%18.29%75.74%
EBIT Margin-1687.36%-1251.12%-2967.41%-2891.06%-576.16%
EBITDA Margin-1674.91%-1234.71%-2903.14%-2833.54%-555.74%
Operating Profit Margin-1683.01%-1226.70%-2888.50%-2545.40%-763.84%
Pretax Profit Margin-1687.36%-1251.12%-2967.41%-2891.06%-576.16%
Net Profit Margin-1686.00%-1248.25%-2946.36%-2846.30%-557.19%
Continuous Operations Profit Margin-1687.36%-1251.12%-2967.41%-2891.06%-576.16%
Net Income Per EBT99.92%99.77%99.29%98.45%96.71%
EBT Per EBIT100.26%101.99%102.73%113.58%75.43%
Return on Assets (ROA)-285.07%-65.35%-216.11%-92.79%-30.35%
Return on Equity (ROE)-398.10%-72.11%-218.94%-91.45%-30.36%
Return on Capital Employed (ROCE)-443.04%-73.31%-232.01%-85.09%-42.10%
Return on Invested Capital (ROIC)-438.07%-73.05%-229.74%-84.62%-41.95%
Return on Tangible Assets-307.76%-69.40%-254.25%-98.96%-31.21%
Earnings Yield-75.14%-11.97%-95.97%-41.73%-14.74%
Efficiency Ratios
Receivables Turnover4.063.011.291.272.11
Payables Turnover0.000.080.771.741.67
Inventory Turnover0.000.000.005.435.91
Fixed Asset Turnover2.111.190.540.691.57
Asset Turnover0.170.050.070.030.05
Working Capital Turnover Ratio0.160.110.050.030.10
Cash Conversion Cycle-183086.89-4647.02-194.10145.4316.29
Days of Sales Outstanding89.97121.44282.77288.38172.92
Days of Inventory Outstanding0.000.000.0067.2061.72
Days of Payables Outstanding183176.864768.47476.87210.14218.34
Operating Cycle89.97121.44282.77355.58234.64
Cash Flow Ratios
Operating Cash Flow Per Share-8.71-0.40-0.89-0.83-0.91
Free Cash Flow Per Share-8.73-0.40-0.91-0.84-0.93
Dividend Paid and CapEx Coverage Ratio-424.07-115.28-34.68-99.19-50.19
Capital Expenditure Coverage Ratio-424.07-115.28-34.68-99.19-50.19
Operating Cash Flow Coverage Ratio-95.59-36.10-35.87-97.61-41.00
Operating Cash Flow to Sales Ratio-14.80-10.68-26.00-19.10-5.52
Free Cash Flow Yield-66.13%-10.33%-87.13%-28.29%-14.90%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-1.33-8.36-1.04-2.40-6.78
Price-to-Sales (P/S) Ratio22.44104.2930.7068.2137.79
Price-to-Book (P/B) Ratio5.306.032.282.192.06
Price-to-Free Cash Flow (P/FCF) Ratio-1.51-9.68-1.15-3.53-6.71
Price-to-Operating Cash Flow Ratio-1.52-9.76-1.18-3.57-6.85
Price-to-Earnings Growth (PEG) Ratio-0.030.160.06-0.070.19
Enterprise Value Multiple-1.20-7.34-0.88-1.61-4.11
Enterprise Value14.15M42.06M5.76M11.66M16.49M
EV to EBITDA-1.20-7.34-0.88-1.61-4.11
EV to Sales20.0490.5925.4545.6422.82
EV to Free Cash Flow-1.35-8.41-0.95-2.37-4.05
EV to Operating Cash Flow-1.35-8.48-0.98-2.39-4.13
Tangible Book Value Per Share1.910.580.341.212.89
Shareholders’ Equity Per Share2.490.650.461.353.02
Tax and Other Ratios
Effective Tax Rate0.000.000.000.000.00
Revenue Per Share0.590.040.030.040.16
Net Income Per Share-9.92-0.47-1.01-1.24-0.92
Tax Burden1.001.000.990.980.97
Interest Burden1.001.001.001.001.00
Research & Development to Revenue11.675.0816.217.211.75
SG&A to Revenue6.160.000.000.000.00
Stock-Based Compensation to Revenue1.221.060.752.950.57
Income Quality0.880.850.880.660.95

Currency in USD